Literature DB >> 7872292

Malignant histiocytosis in a patient presenting with hepatic dysfunction and peliosis hepatis.

K D Fine1, M Solano, D E Polter, G W Tillery.   

Abstract

In this article, we report the case of a 36-yr-old patient presenting with manifestations of portal hypertension, hepatic dysfunction, and fever who proved to have peliosis hepatis on liver biopsy. A thorough work-up revealed no obvious etiology. At autopsy, malignant histiocytosis of the liver and bone marrow was diagnosed. This case represents the first report of the association of peliosis hepatis with this rare histiocytic neoplasm and exemplifies the need for persistence in the search for malignancy, particularly hematological malignancy, in the patient with unexplained peliosis. The clinical similarity of peliosis hepatis associated with hematological malignancy and bacillary peliosis is also discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7872292

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Peliosis hepatis complicated by portal hypertension following renal transplantation.

Authors:  Chia-Ying Yu; Liang-Che Chang; Li-Wei Chen; Tsung-Shih Lee; Rong-Nan Chien; Ming-Fang Hsieh; Kun-Chun Chiang
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome.

Authors:  A K Wong; M Alfert; D H Castrillon; Q Shen; J Holash; G D Yancopoulos; L Chin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

3.  Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome.

Authors:  Yuan Xue; Piotr Religa; Renhai Cao; Anker Jon Hansen; Franco Lucchini; Bernt Jones; Yan Wu; Zhenping Zhu; Bronislaw Pytowski; Yuxiang Liang; Weide Zhong; Paolo Vezzoni; Björn Rozell; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-18       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.